Valuation: Cellink AB

Market Cap 1.41B 149M 128M 119M 109M 205M 14.25B 208M 550M 7.16B 559M 547M 23.67B P/E 2026 *
-6.2x
P/E 2027 * -11.2x
Enterprise Value 1.34B 142M 121M 114M 104M 195M 13.55B 198M 523M 6.81B 532M 520M 22.51B EV / Sales 2026 *
0.83x
EV / Sales 2027 * 0.74x
Free-Float
69.88%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 54 2023-11-26
Director of Finance/CFO 56 2026-02-28
Chief Operating Officer - 2026-01-06
Director TitleAgeSince
Director/Board Member 70 2019-12-17
Director/Board Member 37 2015-02-28
Director/Board Member - 2026-05-06
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 149M
+0.27%+6.97%+25.86%+19.39% 233B
+1.36%+8.10%+3.33%-12.35% 154B
+1.16%-3.98%-20.44%+31.92% 134B
+2.03%-2.82%-52.56%-0.08% 73B
+0.98%+2.26%-16.22%-12.49% 52.24B
-0.04%-1.98%+9.73%+18.19% 51.75B
+1.73%+7.05%+30.72%+35.16% 44.91B
+1.49%-0.36%+35.91%+53.26% 40.35B
+1.03%+1.53%-0.53%+8.54% 33.8B
Average +1.00%+1.76%+1.76%+15.73% 90.71B
Weighted average by Cap. +0.98%+3.00%+2.97%+13.70%

Financials

2026 *2027 *
Net sales 1.62B 171M 147M 137M 126M 236M 16.39B 239M 633M 8.23B 643M 629M 27.23B 1.69B 178M 152M 143M 131M 245M 17.03B 248M 657M 8.56B 668M 654M 28.3B
Net income -227M -23.97M -20.53M -19.21M -17.59M -33.01M -2.29B -33.44M -88.52M -1.15B -90.01M -88.05M -3.81B -126M -13.31M -11.4M -10.66M -9.76M -18.32M -1.27B -18.56M -49.14M -640M -49.96M -48.88M -2.12B
Net Debt -69M -7.29M -6.24M -5.84M -5.35M -10.03M -697M -10.17M -26.91M -350M -27.36M -26.77M -1.16B -166M -17.53M -15.02M -14.05M -12.86M -24.14M -1.68B -24.46M -64.73M -843M -65.82M -64.39M -2.79B
Logo Cellink AB
BICO Group AB, previously Cellink AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company focuses on the application areas of bioprinting, multiomics, cell line development, and diagnostics. The Company develops and markets technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. The Company’s operations divided in two segments: The Industrial Solutions segment that offers products within precision dispensing and biosensor technology for industrial customers, which make a high-capacity contribution to customers production; and The Laboratory Solutions segment that offers 3Dprinters, single- cell and liquid- dispensing instruments as well as services and consumables related to these products.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-